Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Daily News

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

L.A. McKeown

December 17, 2019

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Conference News AHA 2019

No Benefit of Colchicine in All-Comers PCI

Shelley Wood

November 17, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Daily News

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Michael O'Riordan

July 09, 2019

News Conference News EuroPCR 2019

New Clarity on Patients at High Risk for Bleeding After PCI

Michael O'Riordan

May 28, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Conference News HRS 2019

Vagus Nerve Stimulation Lightens Arrhythmia Burden in Patients With Paroxysmal A-fib

Todd Neale

May 09, 2019

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

News Daily News

Signal of Aortic Stenosis Risk With Celecoxib

Michael O'Riordan

March 05, 2019

News Daily News

New Equations Help ID Patients at Low Risk for Bleeding With Aspirin

Michael O'Riordan

February 26, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

Advertisement

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

No Benefit of Colchicine in All-Comers PCI

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

New Clarity on Patients at High Risk for Bleeding After PCI

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Vagus Nerve Stimulation Lightens Arrhythmia Burden in Patients With Paroxysmal A-fib

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Signal of Aortic Stenosis Risk With Celecoxib

New Equations Help ID Patients at Low Risk for Bleeding With Aspirin

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content